CURRICULUM VITAE

**DATE:** August 29, 2021

**NAME:** Amesika Nicole Nyaku

**PRESENT TITLE:** Assistant Professor

**HOME ADDRESS:** 184 Harrison Ave, Jersey City, New Jersey 07304

**OFFICE ADDRESS:** 185 South Orange, MSB I 689, Newark, New Jersey 07103

**TELEPHONE NUMBER/E-MAIL ADDRESS:** 973-972-6214/amesika.nyaku@rutgers.edu

**CITIZENSHIP:** USA

**EDUCATION**:

1. Undergraduate Graduate and Professional

 Northwestern University

 Evanston, IL

 Bachelor of Arts (Chemistry) May 2006

1. Graduate and Professional

 Northwestern University

 Chicago, IL

 Doctor of Medicine May 2010

Northwestern University

 Chicago, IL

 Master of Science (Clinical Investigation) June 2016

**POSTGRADUATE TRAINING:**

A. Internship and Residencies

 Northwestern Memorial Hospital

Internal Medicine

July 2010 – June 2013

Northwestern Memorial Hospital

Infectious Diseases

July 2013 – June 2015

1. Research Fellowships:

Northwestern Memorial Hospital

Infectious Diseases

July 2015 – August 2016

**MILITARY:** none

**ACADEMIC APPOINTMENTS:**

Department of Medicine

Rutgers- New Jersey Medical School

Assistant Professor

August 2016 – present

 **HOSPITAL APPOINTMENTS:**

University Hospital

Attending Physician

September 2016 – present

Northwestern Lake Forest Hospital

Associate Attending Physician

October 2014 – September 2016

**OTHER EMPLOYMENT OR MAJOR VISITNG APPOINTMENTS:** not applicable

**PRIVATE PRACTICE**: not applicable

**LICENSURE:**

Medical Doctor/June 2023

**DRUG LICENSURE:**

 CDS: October 2023, DEA/DATA 2000 waiver: October 2023

**CERTIFICATION:**

Internal Medicine/December 2023

Infectious Diseases/December 2026

**MEMBERSHIPS, OFFICES AND COMMITTEE ASSIGNMENTS IN PROFESSIONAL SOCIETIES:**

Infectious Diseases Society of America

Member

October 2014 - present

HIV Medicine Association

Member

October 2014 – present

International AIDS Society

Member

May 2016 - present

**HONORS AND AWARDS:**

Nomination Golden Apple Award for Teaching

Nominated by: Student Family Health Care Center

March 2018

Chief Fellow, Infectious Diseases

 Awarded by: Northwestern University, Feinberg School of Medicine, Department of Medicine

 July 2014

Design Industries Foundation Fighting AIDS Chicago Fellow

 Awarded by: Design Industries Foundation Fighting AIDS

 July 2014

 Outstanding Infectious Diseases Fellow Teaching Award

Awarded by: Northwestern University, Feinberg School of Medicine, Department of Medicine Division of Infectious Diseases

 July 2014

**BOARDS OF DIRECTORS/TRUSTEES POSITIONS:** none

**SERVICE ON NATIONAL GRANT REVIEW PANELS, STUDY SECTIONS, COMMITTEES:** none

**SERVICE ON MAJOR COMMITTEES:**

1. International:
	1. AIDS Clinical Trial Group Antiretroviral Therapy Strategies Transformative Science Group

 Investigator February 2018 – February 2021

* 1. Study Monitoring Committee of the AIDS Clinical Trial Group Antiretroviral Therapy Strategies Transformative Science Group

Investigator July 2018 – present

1. National: none
2. Medical School/University:
	1. NJMS Addiction Workgroup member July 2018 - current
3. Hospital:
	1. Anti-Infective Subcommittee, Jan 2018 – Sept 2018
4. Department: none
5. Editorial Boards: none
6. *AdHoc* Reviewer
	1. Transplant Infectious Diseases, 2016
	2. HIV Links, 2018
	3. Journal of International Antimicrobial Agents, 2019
	4. Journal of Infectious Diseases, 2020

**SERVICE ON GRADUATE SCHOOL COMMITTEES:** none

**SERVICE ON HOSPITAL COMMITTEES:**

1. Anti-Infective Subcommittee member, Jan 2018 – Aug 2018

**SERVICE TO THE COMMUNITY:**

1. Newark EMA Quality Management Committee Clinical Specialist, Aug 2017 – present
2. DMHAS Stakeholder Constituency Leadership Committee, June 2020-present

**SPONSORSHIP (Primary Mentorship) OF CANDIDATES FOR POSTGRADUATE DEGREE:**

1. Masters
	1. Aparna Akyar – Master of Biomedical Sciences program, Rutgers-Newark SGS 2020

Topic: A Survey of Attitudes of Participants in HIV Prevention Research

1. Doctoral
	1. Faith Pettyjohn – Doctoral Nursing Practice, Rutgers School of Nursing, 2020

Graduate thesis project: Waitlist effects on engagement in treatment for opioid use disorder

**SPONSORSHIP (Primary Mentorship) OF POSTDOCTORAL FELLOWS:**

* 1. Louis Lerebours, MD – Addiction Medicine Fellow, Scholar, Yale REACH Program, 2020

Topic: Engaging and transforming social networks to help reduce drug use

**TEACHING RESPONSIBILITIES:**

1. Lectures or Course Directorships:
	1. Addiction Medicine fellow didactics in core competencies (lectures each year) -2019 (2), 2020 (4),
	2. Infectious Disease fellow didactics in core competencies (lectures each year) – 2016 (2), 2017 (2), 2018 (2), 2019 (2), 2020 (3),
	3. Medicine clerkship didactics in core competencies: Infective Endocarditis (lectures each year) – 2018 (8), 2019 (8), 2020 (online)
	4. Medicine clerkship didactics in core competencies: Sexual Transmitted Infections 8/year - 2018, 2019
	5. Motivational interviewing small group preceptor – 3 hours/year - 2017, 2018
2. Research Training (other than Primary Mentorship)
	1. Post Doctoral Fellows:
		1. ID fellowship research/clinical quality improvement supervisor 2018 – current
	2. Pre Doctoral Students:
		1. Udisa Chowdhury, Rutgers- Newark SGS 2019 – 2020

Topic: PrEP initiation among people who inject drugs

* + 1. Payal Shah, Ha Young Cho, Rutgers- Newark SGS 2020 – Present

Topic: Changes in treatment retention after addition of navigators in a low barrier opioid use disorder clinic

* + 1. Arley Giraldo, Rutgers-NJMS

*Scholar, Hispanic Center of Excellence* 2019 – Present

Topic: Demographics in a low barrier opioid use disorder clinic in an urban setting

* + 1. Serra Akyar, Rutgers-NJMS 2019 – 2020

Topic: Patient satisfaction with shared medical appointments in an urban buprenorphine clinic

* + 1. Richard Wolferz, Rutgers-NJMS 2019 – 2020

Topic: Treatment retention and engagement in OUD care with peer navigation support in an urban buprenorphine clinic

**CLINICAL RESPONSIBILITIES:**

1. Outpatient HIV, HIV prevention, HCV and general infectious diseases care
2. Outpatient based addiction treatment with medications for opioid use disorder
3. Inpatient Infectious Diseases consultation
4. Inpatient General Medicine attending

**GRANT SUPPORT:**

1. Principal Investigator:
	1. NJACTS, Pilot Project Grant Program, Risk Environment Analysis to Inform Overdose Education and Naloxone Distribution (OEND), 8/24/2021-8/23/2022, $50,000
	2. NIH-NIDA, K23 DA053989, Implementing Integrated Services for People with HIV and Opioid Use Disorder, 4/01/2021-03/31/20206, $1,051,885
	3. New York University, School of Medicine, 1U01DA047982, Long-acting buprenorphine vs naltrexone opioid treatments in CJS-involved adults (EXIT-CJS), 08/01/2020-07/31/2024, $2,508,412.04
2. Co-Investigator
	1. SAMHSA, 1H79 TI081510, Opioid Peer Emergency Navigation to Accessing Comprehensive Care and Engaging Specialized Services (OPEN ACCESS), 2/28/2019-2/27/2022, $1,564,554
3. Pending:
	1. ARHQ, R01 13383695, Improving Opioid Recovery and Outcomes for Released Prisoners (co-investigator)
4. Completed
	1. NIH-NIAID, 2 UM1 AI069419-15, Weill Cornell Medical College – New Jersey Medical School Clinical Trials Unit, 10/1/2016-3/31/2021, $2,109,2020 (co-investigator)
	2. New Jersey DHS DMAHS, DR6464, Northern New Jersey Medication Assisted Treatment Center of Excellence, 4/1/2019-6/30/2022, $6,500,000 (co-principal investigator)
	3. Incyte - Novartis, Ruxolitinib in patients with COVID-19 associated cytokine storm (RUXCOVID), 4/27/2020-6/29/2021, $1591,879 (if enrolled), (principal investigator)
	4. NJ DHSTS, DHST20FPR014, DHSTS Federal HIV Prevention Program 2020, 1/1/2021-12/31/2021, $523,000 (physician)
	5. HRSA Ryan White HIV/AIDS Program, Award number not available, Ryan White Part A/F Emergency Relief, 3/1/2020-2/29/2021, $1,342,000 (physician)
	6. HRSA Ryan White HIV/AIDS Program, 5 H76HA28079, Ryan White Part C Outpatient EIS Program, 1/1/2021-12/31/2021 (physician)
	7. NIH-NIAID, T32 A1095207, Northwestern University Infectious Diseases Education and Science, 8/1/2014-7/31/2016 (trainee)

**PUBLICATIONS:**

1. Refereed Original Article in Journal
	1. Treitler PC, Bowden CF, Lloyd, J, Enich M, **Nyaku AN**, et al. et al. Perspectives of opioid use disorder treatment providers during COVID-19: Adapting to flexibilities and sustaining reforms. J Subst Abuse Treat 132, 108514 (2021). [epub ahead of print]
	2. Waddell EN, Springer SA, Marsch LA, Farabee, D, Schwartz PA, **Nyaku A**, et al. Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults (EXIT-CJS). Journal of Substance Abuse Treatment 108389 (2021) doi:10.1016/j.jsat.2021.108389.
	3. Corey L, **HVTN 704/HTPN 085 and HVTN 703/HPTN 081 Study Teams**, et al. Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition. N Engl J Med 384, 1003–1014 (2021).
	4. Baden LR, **COVE Study Group**, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med 384, 403–416 (2021).
	5. Taiwo BO, Quiñones-Mateu ME, Smith K, Zeng L, Gulick R, **Nyaku AN**, et al. Prior Case of Resistance on Dolutegravir Plus Lamivudine Dual Therapy. AIDS Res Hum Retroviruses 2020; 36:254–255.
	6. Li JZ, Sax PE, Marconi VC, Fajnzylber J, Berzins B, **Nyaku AN**, et al. No Significant Changes to Residual Viremia After Switch to Dolutegravir and Lamivudine in a Randomized Trial. Open Forum Infect Dis 2019; 6:ofz056.
	7. **Nyaku AN**, Zheng L, Gulick RM, et al. Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA <500 000 copies/mL: week 48 outcomes from ACTG 5353. J Antimicrob Chemother 2019; 74:1376–1380.
	8. Taiwo BO, Zheng L, Stefanescu A, **Nyaku A**, Bezins B, Wallis CL, et al. ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)-infected Participants With HIV-1 RNA <500000 Copies/mL. Clin Infect Dis. 2018 May 17;66(11):1689–97.
	9. Taiwo BO, Marconi VC, Berzins B, Moser CB, **Nyaku AN**, Fichtenbaum CJ, et al. Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized Trial. Clin Infect Dis. 2018 May 17;66(11):1794–7.
	10. Morgan E, **Nyaku AN**, DʼAquila RT, Schneider JA. Determinants of HIV Phylogenetic Clustering in Chicago Among Young Black Men Who Have Sex With Men From the uConnect Cohort. J Acquir Immune Defic Syndr. 2017 01;75(3):265–70.
	11. **Nyaku AN**, Williams LM, Galvin SR. Comparison of HIV Testing Uptake in an Urban Academic Emergency Department Using Different Testing Assays and Support Systems. AIDS Patient Care STDS. 2016 Apr;30(4):166–9.
2. Books, Monographs and Chapters: none
3. Patents Held: none
4. Other Articles (Reviews, Editorials, etc.) In Journals; Chapters; Books; other Professional Communications
	1. **Nyaku, AN**, Advances in Two-Drug Antiretroviral Regimens, *HIV Specialist*, 10, 20-23, 2018
	2. **Nyaku, AN,** Kelly, SG, & Taiwo, BO, Long-Acting Antiretrovirals: Where Are We now? *Current HIV/AIDS Reports*, 14, 63-71, 2017
	3. Kelly, SG, **Nyaku, AN**, & Taiwo, BO, Two-Drug Treatment Approaches in HIV: Finally Getting Somewhere? *Drugs*, 76, 523-31, 2016
5. Abstracts
6. Akyar S, **Nyaku A**, *et al*. Patient Satisfaction with Shared Medical Appointments Among Patients with Opioid Use Disorder Attending an Urban Buprenorphine Clinic. American Academy of Addiction Psychiatry 31st Annual Meeting and Scientific Symposium, Dec 10-12, 2020.
7. Sudyn AW, Paer JM, Kodali S, Maldonado S, **Nyaku A**, Swaminathan S. Linkage to Care Outcomes among Known HIV-Positive Patients at a High Prevalence Urban Hospital Emergency Department. IDWeek 2020, Sept 21-Sept 30, 2020. Abstract 962.
8. Kodali S, Paer JM, Sudyn AW, Maldonado S, **Nyaku A**, Swaminathan S. The Impact of Opt-Out HIV Screening and Patient Navigator-Assisted Linkage to Care of Newly Diagnosed Persons with HIV in a High-Prevalence Emergency Department. IDWeek 2020, Sept 21-Sept 30, 2020. Abstract 968.
9. Fabricant S, **Nyaku A**, Dalla-Piazza ML. Integrating buprenorphine into an urban HIV primary care practice: Outcomes on viral load suppression and opioid use. IDWeek 2020, Sept 21-Sept 30, 2020. Abstract 1025.
10. Han MK, Bender Ignacio RA, Lopez Bernus A, Milger-Kneidinger, K, **Nyaku AN**, *et al*. RUXCOVID: a phase 3, randomized, placebo-controlled study evaluating the efficacy and safety of ruxolitinib in patients with COVID-19-associated cytokine storm (NCT04362137). AACR Virtual Meeting: COVID-19 and Cancer, July 20-22, 2020.
11. Li J, Sax P, Marconi V, Fajnzylber J, Berzins B, **Nyaku A**, *et al.* No significant changes to residual viremia after switch to dolutegravir and lamivudine in a randomized trial. HIV Drug Therapy, Glasgow 2018, October 28-31, 2018, Glasgow. Abstract O145.
12. Chew D, Tejura N, Closeil G, **Nyaku A**, Swaminathan, S. Challenges in PrEP Implementation in an Urban Infectious Diseases Clinic with a High Background HIV Prevalence. 2018 STD Prevention Conference, August 27-30, 2018, Washington, DC.
13. Taiwo, BO, Zheng, L, **Nyaku, AN**, et al.; ACTG A5353: a pilot study of dolutegravir (DTG) + lamivudine (3TC) for initial treatment of HIV-1-infected participants with HIV-1 RNA < 500,000 copies/mL.; Presented at IAS, 2017; MOAB0107LB
14. Taiwo, BO, Marconi, V, Berzins, B, Janulis, P, **Nyaku, AN**, et al.; Dolutegravir plus lamivudine maintains HIV-1 suppression through week 48 in a pilot randomized trial, Presented at EACS, 2017; PE8/5
15. **Nyaku, A**; Morgan, E; Penugonda, S; Galvin, S; D’Aquila, R; Schneider, J; Molecular Correlates of Young Black Men who have Sex with Men Sexual Networks; Presented at Third Coast CFAR Symposium, 2016
16. Morgan, E; **Nyaku, A**; D’Aquila, R; Schneider, J; Using phylogenetics of HIV to inform prevention among young men who have sex with men in Chicago; Presented at AIDS, 2016; THAX0103
17. Shannon, G and **Nyaku, A**; Comparison of HIV Testing Uptake in an Urban Academic Emergency Department Using Different Testing Assays and Support Systems; Presented at AIDS, 2014; WEPE027
18. Reports: none

**MEDIA**

1. Periodicals
	1. Op-Ed: 3 steps to save lives as NJ’s opioid addictions rise, by Erin Zerbo and Amesika Nyaku. The Star-Ledger, nj.com, September 30, 2020.
	2. Patients and Psychiatrists Alike Face Hurdles in Buprenorphine Prescribing, Psychiatric News, November 15, 2019, 54(22) https://doi.org/10.1176/appi.pn.2019.11a1
	3. On the Frontlines of the Opioid Epidemic, Pulse Magazine, Fall 2019

https://issuu.com/rutgersnjms/docs/pulse\_-\_fall\_2019\_-\_9x11\_-\_digital\_version/10

* 1. HIV Prevention – Nothing About Us Without US!, HOT97, July 13, 2017

https://www.hot97.com/hot-events/made-hot-by/hiv-prevention-nothing-about-us-without-us/

1. Appearances
	1. Clinical Literacy Pertaining to COVID-19 – Elmwood Health Ministry - May 21st, 2021
	2. COVID-19 Vaccine: Facts & Myths – The Newark Public Library – May 4th, 2021
	3. Inclusion and Diversity in Clinical Trials: Actionable Steps to Drive Lasting Change – Duke Clinical Research Institute - April 28th, 2021
	4. Abolish the Drug War – Seton Hall University – March 30th, 2021
	5. COVID-19 & Vaccines -Greater Newark Healthcare Coalition- March 23rd, 2021
	6. New Jersey Black Legislative Caucus/ New Jersey Medical Association Colloquium – January 21, 2021
	7. Morristownship Town Hall on COVID-19 Vaccines – January 19, 2021
	8. NJ Let’s Get Vaccinated -New Jersey Department of Health - January 13, 2021
	9. African Community COVID-19 Vaccine Awareness: What you Should Know – Dec 29, 2020
	10. Continuing the Conversation about COVID-19 Clinical Trials, hosted by University Hospital, NJ, October 12, 2020
	11. Conspiracies & COVID in Communities of Color, hosted by Rutgers New Jersey Medical School Clinical Research Center, October 1, 2020
	12. Pros & Cons of Africans and African Americans Participating in the COVID-19 Vaccine Clinical Trial, hosted by Skadek Network International, INC, September 24, 2020

**PRESENTIONS:**

1. Scientific *(Basic Science)*: none
2. Professional *(Clinical)*:
	1. Integrating Substance Use Treatment in Primary Clinical Setting. October 17, 2020. Northeast/Caribbean AIDS Education & Training Program.
	2. U=U and PrEP: tools for ending the HIV epidemic. December 20, 2019. Rutgers NJ Project ECHO.
	3. Updates on HIV prevention. November 27, 2019. Rutgers New Jersey Medical School. Department of Medicine Internal Residents.
	4. Treating Patients with Opioid Use Disorders Outside of Addiction Clinics. November 26, 2019. Rutgers New Jersey Medical School Internal Medicine Grand Rounds.
	5. From Bending the Curve to Ending the Epidemic: the NYC and NJ Experience. November 1, 2019. SE AETC and TN AETC 22nd Annual Symposium
	6. Medical Comorbidities. July 26, 2019. American Society of Addiction Medicine Review Course.
	7. Dolutegravir plus lamivudine for initial treatment of HIV-1 infected participants with HIV-1 RNA < 500,000 copies/mL: week 48 outcomes from ACTG 5353. June 18, 2019. AIDS Clinical Trials Group Network Meeting, 2019.
	8. Updates on HIV Prevention. March 22, 2019. ACP New Jersey Chapter Annual Scientific Meeting 2019.
	9. Fungal infections in hepatology February 27, 2019. Rutgers New Jersey Medical School. Division of Gastroenterology/Hepatology.
	10. Bending the curve –utilizing treatment as prevention to end the HIV/AIDS epidemic. November 28, 2018. World AIDS day 2018. Rutgers New Jersey Medical School.
	11. Infections in end stage liver disease. January 24, 2018. Rutgers New Jersey Medical School. Division of Gastroenterology/Hepatology.
	12. HIV prevention. Rutgers New Jersey Medical School. Preventive Medicine Educational Conference May 7, 2018.
	13. “Closing the Gap” Health Symposium. Lunch with the Expert. Newark Community Health Advisory Council. April 11, 2018
	14. HIV in the ED. Crozer-Chester Emergency Medicine Residency Grand Rounds, 2016
	15. Long-acting Antiretrovirals: Promise and Pitfalls. AIDS Clinical Trials Group Network Meeting, 2016
	16. Molecular Surveillance of HIV in Young Black Men who have Sex with Men in Chicago: from the bench to public health and prevention. Northwestern University Feinberg School of Medicine Infectious Diseases Research Symposium, 2016